VINC vs. FLGC, TRAW, TLPH, NERV, NRSN, TNXP, GLYC, VBIV, GLTO, and EDSA
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Flora Growth (FLGC), Traws Pharma (TRAW), Talphera (TLPH), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), Tonix Pharmaceuticals (TNXP), GlycoMimetics (GLYC), VBI Vaccines (VBIV), Galecto (GLTO), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Vincerx Pharma has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.
Vincerx Pharma has higher earnings, but lower revenue than Flora Growth.
44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 22.9% of Vincerx Pharma shares are owned by insiders. Comparatively, 17.6% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vincerx Pharma has a net margin of 0.00% compared to Flora Growth's net margin of -75.95%. Flora Growth's return on equity of -144.44% beat Vincerx Pharma's return on equity.
Vincerx Pharma currently has a consensus price target of $5.00, indicating a potential upside of 624.01%. Flora Growth has a consensus price target of $6.00, indicating a potential upside of 358.02%. Given Vincerx Pharma's higher probable upside, research analysts plainly believe Vincerx Pharma is more favorable than Flora Growth.
In the previous week, Flora Growth had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 10 mentions for Flora Growth and 8 mentions for Vincerx Pharma. Flora Growth's average media sentiment score of 0.26 beat Vincerx Pharma's score of -0.24 indicating that Flora Growth is being referred to more favorably in the news media.
Vincerx Pharma received 6 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 64.52% of users gave Vincerx Pharma an outperform vote while only 60.87% of users gave Flora Growth an outperform vote.
Summary
Vincerx Pharma beats Flora Growth on 7 of the 13 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
